Value-based indication-specific pricing and weighted-average pricing: estimated price and cost savings for cancer drugs
Objectives For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to th...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
April 2025
|
| In: |
PharmacoEconomics
Year: 2025, Jahrgang: 43, Heft: 4, Pages: 415-427 |
| ISSN: | 1179-2027 |
| DOI: | 10.1007/s40273-024-01448-x |
| Online-Zugang: | Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s40273-024-01448-x Verlag, kostenfrei, Volltext: http://link.springer.com/article/10.1007/s40273-024-01448-x 
|
| Verfasserangaben: | Daniel Tobias Michaeli, Thomas Michaeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1920418199 | ||
| 003 | DE-627 | ||
| 005 | 20250717002621.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 250324s2025 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40273-024-01448-x |2 doi | |
| 035 | |a (DE-627)1920418199 | ||
| 035 | |a (DE-599)KXP1920418199 | ||
| 035 | |a (OCoLC)1528043636 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Michaeli, Daniel |d 1997- |e VerfasserIn |0 (DE-588)1277183244 |0 (DE-627)1830345109 |4 aut | |
| 245 | 1 | 0 | |a Value-based indication-specific pricing and weighted-average pricing |b estimated price and cost savings for cancer drugs |c Daniel Tobias Michaeli, Thomas Michaeli |
| 264 | 1 | |c April 2025 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Online veröffentlicht: 30. Dezember 2024 | ||
| 500 | |a Gesehen am 24.03.2025 | ||
| 520 | |a Objectives For US Medicare and Medicaid, single drug prices do not reflect the value of supplemental indications. Value-based indication-specific and weighted-average pricing has been suggested for drugs with multiple indications. Under indication-specific pricing, a distinct price is assigned to the differential value a drug offers in each indication. Under weighted-average pricing, a single drug price is calculated that reflects the value and/or volume of each indication. This study estimates price reductions and cost savings for cancer drugs under value-based indication-specific pricing and weighted-average pricing. Methods We collected data on US Food and Drug Administration (FDA)-approved cancer drugs and indications (2003-2020) from FDA labels, the Global Burden of Disease study, clinicaltrials.gov, and Medicare and Medicaid. A multivariable regression analysis, informed by characteristics of original indications, was used to predict value-based indication-specific prices for supplemental indications. These indication-specific prices were combined with each indication’s prevalence data to estimate value-based weighted-average prices and potential cost savings under each policy. Results We identified 123 cancer drugs with 308 indications. Medicare and Medicaid spent a total of $28.2 billion on these drugs in 2020. Adopting value-based indication-specific pricing would increase drug prices by an average of 3.9%, with cost savings of $3.0 billion (10.6%). However, 43.7% higher prices for ultra-rare diseases would increase spending by 16.8% ($44 million). Adopting value-based weighted-average pricing would reduce prices by an average of 4.6% and spending by $3.0 billion (10.6%). Under weighted-average pricing, prices for and spending on ultra-rare diseases would be reduced by 22.6% and $55 million, respectively. Conclusions Value-based indication-specific and weighted-average pricing could help to align the value and price of new indications, thereby reducing expenditure on drugs with multiple indications. | ||
| 700 | 1 | |a Michaeli, Christoph T. |d 1992- |e VerfasserIn |0 (DE-588)1277182337 |0 (DE-627)1830343769 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PharmacoEconomics |d Berlin [u.a.] : Springer, 1992 |g 43(2025), 4 vom: Apr., Seite 415-427 |h Online-Ressource |w (DE-627)327645717 |w (DE-600)2043876-X |w (DE-576)273880853 |x 1179-2027 |7 nnas |a Value-based indication-specific pricing and weighted-average pricing estimated price and cost savings for cancer drugs |
| 773 | 1 | 8 | |g volume:43 |g year:2025 |g number:4 |g month:04 |g pages:415-427 |g extent:13 |a Value-based indication-specific pricing and weighted-average pricing estimated price and cost savings for cancer drugs |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s40273-024-01448-x |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u http://link.springer.com/article/10.1007/s40273-024-01448-x |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20250324 | ||
| 993 | |a Article | ||
| 994 | |a 2025 | ||
| 998 | |g 1277182337 |a Michaeli, Christoph T. |m 1277182337:Michaeli, Christoph T. |d 60000 |d 63600 |d 60000 |e 60000PM1277182337 |e 63600PM1277182337 |e 60000PM1277182337 |k 0/60000/ |k 1/60000/63600/ |k 0/60000/ |p 2 |y j | ||
| 998 | |g 1277183244 |a Michaeli, Daniel |m 1277183244:Michaeli, Daniel |p 1 |x j | ||
| 999 | |a KXP-PPN1920418199 |e 4691318437 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"Value-based indication-specific pricing and weighted-average pricing","title":"Value-based indication-specific pricing and weighted-average pricing","subtitle":"estimated price and cost savings for cancer drugs"}],"person":[{"given":"Daniel","family":"Michaeli","role":"aut","roleDisplay":"VerfasserIn","display":"Michaeli, Daniel"},{"given":"Christoph T.","family":"Michaeli","role":"aut","roleDisplay":"VerfasserIn","display":"Michaeli, Christoph T."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"note":["Online veröffentlicht: 30. Dezember 2024","Gesehen am 24.03.2025"],"recId":"1920418199","language":["eng"],"origin":[{"dateIssuedKey":"2025","dateIssuedDisp":"April 2025"}],"id":{"doi":["10.1007/s40273-024-01448-x"],"eki":["1920418199"]},"name":{"displayForm":["Daniel Tobias Michaeli, Thomas Michaeli"]},"physDesc":[{"extent":"13 S."}],"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Springer ; Adis Intern.","dateIssuedKey":"1992","dateIssuedDisp":"1992-","publisherPlace":"Berlin [u.a.] ; Auckland"}],"id":{"zdb":["2043876-X"],"eki":["327645717"],"issn":["1179-2027"]},"pubHistory":["1.1992 -"],"part":{"text":"43(2025), 4 vom: Apr., Seite 415-427","volume":"43","extent":"13","year":"2025","issue":"4","pages":"415-427"},"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 15.05.14"],"disp":"Value-based indication-specific pricing and weighted-average pricing estimated price and cost savings for cancer drugsPharmacoEconomics","language":["eng"],"recId":"327645717","title":[{"title_sort":"PharmacoEconomics","title":"PharmacoEconomics","subtitle":"economic evaluations of drug therapy in disease management"}]}]} | ||
| SRT | |a MICHAELIDAVALUEBASED2025 | ||